Literature DB >> 17875997

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.

Tatiana Bogdanovich1, Catherine Clark, Klaudia Kosowska-Shick, Bonifacio Dewasse, Pamela McGhee, Peter C Appelbaum.   

Abstract

Among 203 strains of Staphylococcus aureus, the MICs of CG400549 were 0.06 to 1.0 microg/ml, with MIC(50) and MIC(90) values of 0.25 microg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 microg/ml). The daptomycin MICs were 0.25 to 2.0 microg/ml for methicillin-susceptible and 0.25 to 4.0 microg/ml against methicillin-resistant strains (including vancomycin-intermediate strains). Single-passage selection testing showed low resistance frequencies with CG400549, but multistep analysis showed that CG400549 yielded resistant mutants after 14 to 17 days in all strains tested.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17875997      PMCID： PMC2151435          DOI： 10.1128/AAC.00550-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  First case of VRSA identified in Michigan.

Authors:  Judene Bartley
Journal:  Infect Control Hosp Epidemiol       Date:  2002-08       Impact factor: 3.254

2.  Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis.

Authors:  R J Heath; Y T Yu; M A Shapiro; E Olson; C O Rock
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

3.  Triclosan targets lipid synthesis.

Authors:  L M McMurry; M Oethinger; S B Levy
Journal:  Nature       Date:  1998-08-06       Impact factor: 49.962

4.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

5.  The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.

Authors:  H Bergler; S Fuchsbichler; G Högenauer; F Turnowsky
Journal:  Eur J Biochem       Date:  1996-12-15

6.  A mechanism of drug action revealed by structural studies of enoyl reductase.

Authors:  C Baldock; J B Rafferty; S E Sedelnikova; P J Baker; A R Stuitje; A R Slabas; T R Hawkes; D W Rice
Journal:  Science       Date:  1996-12-20       Impact factor: 47.728

7.  Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus.

Authors:  T L Bannerman; G A Hancock; F C Tenover; J M Miller
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

8.  Vancomycin-resistant Staphylococcus aureus--New York, 2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-04-23       Impact factor: 17.586

9.  Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database.

Authors:  Linda K McDougal; Christine D Steward; George E Killgore; Jasmine M Chaitram; Sigrid K McAllister; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania.

Authors:  Fred C Tenover; Linda M Weigel; Peter C Appelbaum; Linda K McDougal; Jasmine Chaitram; Sigrid McAllister; Nancye Clark; George Killgore; Caroline M O'Hara; Laura Jevitt; Jean B Patel; Bülent Bozdogan
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191
View more
  7 in total

Review 1.  Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?

Authors:  Joshua B Parsons; Charles O Rock
Journal:  Curr Opin Microbiol       Date:  2011-08-20       Impact factor: 7.934

2.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

3.  Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study.

Authors:  David J Farrell; Marion Robbins; William Rhys-Williams; William G Love
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

Review 4.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

5.  Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains.

Authors:  Catherine Clark; Klaudia Kosowska-Shick; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

6.  A pathway-directed positive growth restoration assay to facilitate the discovery of lipid A and fatty acid biosynthesis inhibitors in Acinetobacter baumannii.

Authors:  Daryl L Richie; Lisha Wang; Helen Chan; Gianfranco De Pascale; David A Six; Jun-Rong Wei; Charles R Dean
Journal:  PLoS One       Date:  2018-03-05       Impact factor: 3.240

7.  The two functional enoyl-acyl carrier protein reductases of Enterococcus faecalis do not mediate triclosan resistance.

Authors:  Lei Zhu; Hongkai Bi; Jincheng Ma; Zhe Hu; Wenbin Zhang; John E Cronan; Haihong Wang
Journal:  MBio       Date:  2013-10-01       Impact factor: 7.867
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.